Secondary Leukemia (Sl)/Myelodysplasia (MDS) and Bone Marrow (BM) Chromosomal Aberrations after Dose-Intensive Chemotherapy for Neuroblastoma (NB).

Abstract

We previously described SL/MDS in 3/53 newly-diagnosed NB patients (pts) who received 4 cycles of high-dose cyclophosphamide (4200 mg/m2)-doxorubicin (75 mg/m2)-vincristine (CAV) and 3 cycles of high-dose cisplatin (200 mg/m2)-etoposide (600 mg/m2) (P/E), ± local radiotherapy (RT), ± immunotherapy using the anti-GD2 3F8 antibody, ± targeted RT using 131-I-3F8. With longer follow-up and the addition of a further 11 pts who received 7 cycles and 5 pts who received 6 cycles, there are 3 more cases of SL/MDS (Table1), which gives SL or MDS in 6/69 pts.Table 1. Pts with Secondary Leukemia or MDSAgeFrom DxPresentationTypeCytogeneticsPreviously reported cases (J Clin Oncol 16:3880, 1998)*4y15msurveillance BMM2del(9)(q13q34),del(11)(q23q25)5y27mthrombocytopeniaMDSdel(5)(q11), der(7)t(7;17)(q11,q11), −1712y7mmonocytosisM5del(11)(q23) (rearranged MLL gene)New cases**3y12mleukocytosisALLt(4;11)(q21;q23) (rearranged MLL)8y50mthrombocytopeniaMDSdel(5q) and del(7q)25y24mthrombocytopeniaMDSdel(7q)* all 3 received 7 cycles; 2 also received local RT and 3F8** all 3 received 7 cycles, local RT, 3F8, and 131-I-3F8This SL risk was a reason for subsequently limiting induction to 3 CAV and 2 P/E. At 4+-to-72+ months (median, 19+), SL/MDS has not occurred in 46 pts treated with 5 cycles, including 19 who received thiotepa-topotecan-carboplatin (TTC) with an autologous stem-cell transplant and 11 who received both TTC and oral etoposide (E) maintenance.In routine surveillance studies, 4 pts in the 6/7-cycle group had BM cytogenetic changes (worrisome for SL) that spontaneously resolved, and 1 pt in the 5-cycle group had a cytogenetic aberration that has persisted in >90% of BM cells for 15+ months, without morphologic or clinical evidence of SL/MDS (Table 2). Allo-transplant was recommended, but not done, for this patient and for the 10 yr old with a t(3;6) translocation that was documented in 20%-to-100% of BM mitoses for 26 months before finally disappearing (Table 2).Table 2. Pts with chromosomal aberrations but no SL or MDSAgeFrom Dx# of Cycles, other Rx*Cytogenetics, Duration18y10m7, local RTinv(11)(q21q23) (rearranged MLL), 1m6y21m7, local RT, 131-I-3F8t(2;16)(q31;q22) t(6;10)(q21;p13), 4m10y22m6, local RT, 131-I-3F8der(6) t(3,6)(q23, p25), 26m6y24m7, local RT, 131-I-3F8dup(1)(q21q32), 14m5y17m5, local RT, TTC, oral Et(4;11)(p12;q23) (rearranged MLL), 15m+* all of these pts also received 3F8In prior-treated NB pts, we also found transient BM cytogenetic abnormalities, some associated with leukemia or MDS, including del(16) (q22) and del(7q), though others are not, including inv(17) (p13q23).We conclude that fewer cycles of dose-intensive induction may reduce risks of SL/MDS and that BM cytogenetic abnormalities do not invariably evolve into SL or MDS. The nature of other genetic or epigenetic abnormalities that underlie such a transformation is currently unknown.